Global Nonalcoholic Steatohepatitis (NASH) Pipeline Analysis 2015

Jul 28, 2015, 08:12 ET from Research and Markets

DUBLIN, July 21, 2015 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Nonalcoholic steatohepatitis (NASH) - Pipeline Analysis" report to their offering.

This report gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression biomarkers.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space.

NASH is associated with fatty liver, hepatic inflammation, hepatocyte injury and fibrogenesis and may worsen into fibrosis or cirrhosis, liver failure and rarely into liver cancer. Currently, there are no approved drugs for NASH by U.S. Food and Drug Administration (FDA) and there a high unmet clinical need. NASH, if untreated can progress to liver-destroying cirrhosis and potentially cancer. Majority of the NASH pipeline drugs are from specialised small to mid pharmaceutical & biotech companies.

As some of the candidates are nearing key R&D milestones, there is a huge competition among large pharmaceutical and biotech companies to acquire these assets. Gilead's acquisition of Phenex FXR program & Boehringer's acquisition of NASH clinical asset from Pharmaxis supports this trend. Diagnosis of NASH still requires histological confirmation and there is a great demand for specific non-invasive diagnosis for distinguishing NASH from other liver diseases. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH.

There is a tremendous opportunity for upcoming therapies specific to NASH such as MAbs, RNA-based therapies & Recombinant proteins. These modalities may provide Anti-fibrosis, Anti-inflammatory and metabolic benefits.

Key Topics Covered:

1. Report Description

2. Introduction

3. Hot Targets, Mechanisms & Therapies

4. Market Data 

5. Pipeline Analysis

6. Small Molecules

7. Large Molecule

8. RNA-based Therapy

9. Recombinant Proteins

10. Antibodies

11. Large Molecules (Unspecified)

12. Other Molecules

13. NASH Drug Analysis based on Mechanisms

14. Major Players

- Boehringer Ingelheim

- Cerenis Therapeutics

- Connexios Life Sciences

- Genfit

- Gilead Sciences

- Intercept

- Islet Sciences

- Nimbus Therapeutics

- Verva Pharmaceuticals

- Viking Therapeutics

For more information visit

Media Contact:

Laura Wood, +353-1-481-1716,


SOURCE Research and Markets